C2orf40蛋白在鼻咽癌中的表达及意义

doi:10.3760/cma.j.issn.1673-422X.2017.06.002

摘要/Abstract

摘要： 目的探讨C2orf40蛋白在鼻咽癌组织和细胞中的表达及其与细胞分化、临床病理特征的关系。方法收集2001年1月至2003年12月在汕头大学医学院附属肿瘤医院诊断为鼻咽癌的122例病理活检组织石蜡标本及其病历资料，另外收集25例慢性鼻咽炎的石蜡标本作为对照。采用免疫组织化学法检测C2orf40蛋白表达情况，同时分析C2orf40表达水平与临床病理特征的关系。体外实验应用Western blotting对鼻咽癌细胞株CNE1、CNE2和C6661进行C2orf40蛋白表达的测定，分析C2orf40表达与细胞分化程度的关系。结果C2orf40在对照组的阳性率为96.0%(24/25)，且88.0%为高表达，病例组阳性率为58.2%（71/122），但82.0%为低表达，二者差异有统计学意义（U=255.500，P＜0.001）。C2orf40表达与淋巴结转移分期（N分期）和临床分期呈负相关（r=-0.058，P＜0.001；r=-0.202，P=0.026）。C2orf40在高分化鼻咽癌细胞株CNE1中呈高表达，在低分化鼻咽癌细胞株CNE2和C6661中呈低表达。结论C2orf40蛋白表达下调与肿瘤细胞分化、淋巴结转移和临床分期相关，是鼻咽癌发生、发展的分子事件之一，可能成为抗肿瘤治疗的潜在靶点。

关键词: 鼻咽肿瘤, 病理学, 临床, C2orf40

Abstract: ObjectiveTo evaluate the protein expression of chromosome 2 open reading frame 40 (C2orf40) in nasopharyngeal carcinoma (NPC) tissues and cells, and to explore its association with cell differentiation and clinicopathological features. MethodsA total of 122 patients with NPC between January 2001 and December 2003 were enrolled in Cancer Hospital of Shantou University Medical College. The paraffinembedded tissue sections and medical records were collected. Twentyfive samples with chronic nasopharyngitis were used as controls. Tumor and control tissues from biopsies underwent immunohistochemical staining for C2orf40. C2orf40 expression was analyzed with clinicopathological variables. Besides, the protein expressions of C2orf40 were measured by Western blotting in three NPC cell lines, including CNE1, CNE2 and C6661. ResultsNinetysix percent (24/25) of control tissues showed positive expression, among which 88.0% showed dense staining. Otherwise, only 58.3% (71/122) of NPC samples were positive for C2orf40 protein and 82.0% showed weak staining. There was significantly difference between the two groups (U=255.500, P＜0.001). It was inversely related to lymph nodes status (r=-0.058, P＜0.001) and clinical stage (r=-0.202, P=0.026) by Spearman rank correlation test. In vitro, higher level of C2orf40 protein was found in well differentiated CNE1 cells, while lower levels were found in poorly differentiated cell lines CNE2 and C6661. ConclusionDownregulated C2orf40 expression is correlated with tumor cell differentiation, lymph nodes metastasis and clinical stage, and may be a molecular event in the occurrence and development of NPC. C2orf40 is likely to be a potential target of anticancer therapy.

Key words: Nasopharyngeal neoplasms, Pathology, clinical, C2orf40

彭琳，黄裔腾，陈炯玉，洪超群，吴晓. C2orf40蛋白在鼻咽癌中的表达及意义[J]. 国际肿瘤学杂志, 2017, 44(6): 406-.

Peng Lin, Huang Yiteng, Chen Jiongyu, Hong Chaoqun, Wu Xiao. Expression of C2orf40 protein and its clinical significance in human nasopharyngeal carcinoma[J]. Journal of International Oncology, 2017, 44(6): 406-.

参考文献

［1］苏涛, 刘海玲, 陆士新. 人食管癌相关基因cDNA片段的克隆与初步鉴定［J］. 中华肿瘤杂志, 1998, 20(4): 14-17. DOI: 10.3760/j.issn:02533766.1998.04.004. ［2］ Mori Y, Ishiguro H, Kuwabara Y, et al. Expression of ECRG4 is an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma［J］. Oncol Rep, 2007, 18(4): 981-985. ［3］ Goetze S, Feldhaus V, Traska T, et al. ECRG4 is a candidate tumor suppressor gene frequently hypermethylated in colorectal carcinoma and glioma［J］. BMC Cancer, 2009, 9: 447. DOI: 10.1186/147124079447. ［4］ Wang YB, Ba CF. Promoter methylation of esophageal cancerrelated gene 4 in gastric cancer tissue and its clinical significance［J］. Hepatogastroenterology, 2012, 59(118): 1696-1698. DOI: 10.5754/hge12258. ［5］ Sabatier R, Finetti P, Adelaide J, et al. DownRegulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer［J］. PLoS One, 2011, 6(11): e27656. DOI: 10.1371/journal.pone.0027656. ［6］ Vanaja DK, Ehrich M, Van Den Boom DA, et al. Hypermethylation of genes for diagnosis and risk stratification of prostate cancer［J］. Cancer Invest, 2009, 27(5): 549-560. DOI: 10.1080/07357900802620794. ［7］ Li LW, Yu XY, Yang Y, et al. Expression of esophageal cancer related gene 4 (ECRG4), a novel tumor suppressor gene, in esophageal cancer and its inhibitory effect on the tumor growth in vitro and in vivo［J］. Int J Cancer, 2009, 125(7): 1505-1513. DOI: 10.1002/ijc.24513. ［8］ You YJ, Yang WJ, Qin X, et al. ECRG4 acts as a tumor suppressor and as a determinant of chemotherapy resistance in human nasopharyngeal carcinoma［J］. Cell Onco (Dordr), 2015, 38(3): 205-214. DOI: 10.1007/s134020150223y. ［9］ Ho FC, Tham IW, Earnest A, et al. Patterns of regional lymph node metastasis of nasopharyngeal carcinoma: a metaanalysis of clinical evidence［J］. BMC Cancer, 2012, 12: 98. DOI: 10.1186/147124071298. ［10］ Lu J, Wen MX, Huang YR, et al. C2ORF40 suppresses breast cancer cell proliferation and invasion through modulating expression of M phase cell cycle genes［J］. Epigenetics, 2013, 8(6): 571-583. DOI: 10.4161/epi.24626. ［11］ Xu T, Xiao DJ, Zhang X. ECRG4 inhibits growth and invasiveness of squamous cell carcinoma of the head and neck in vitro and in vivo［J］. Oncol Lett, 2013, 5(6): 1921-1926. DOI: 10.3892/ol.2013.1298. ［12］ Li LW, Li YY, Li XY, et al. A novel tumor suppressor gene ECRG4 interacts directly with TMPRSS11A (ECRG1) to inhibit cancer cell growth in esophageal carcinoma［J］. BMC Cancer, 2011, 11: 52. DOI: 10.1186/147124071152. ［13］ Matsuzaki J, Torigoe T, Hirohashi Y, et al. Expression of ECRG4 is associated with lower proliferative potential of esophageal cancer cells［J］. Pathol Int, 2013, 63(8): 391-397. ［14］秦鑫, 游颜杰, 张文静, 等. 上调ECRG4表达对鼻咽癌CNE1细胞增殖、克隆形成和侵袭的影响［J］. 现代肿瘤医学, 2016, 24(2): 184-186. DOI: 10.3969/j.issn.16724992.2016.02.004. ［15］ Yue CM, Deng DJ, Bi MX, et al. Expression of ECRG4, a novel esophageal cancerrelated gene, downregulated by CpG island hypermethylation in human esophageal squamous cell carcinoma［J］. World J Gastroenterol, 2003, 9(6): 1174-1178.

[1]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[2]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[3]	陈琦, 徐晨阳, 王寅, 雷大鹏. 高光谱成像在头颈部肿瘤诊疗中的应用现状[J]. 国际肿瘤学杂志, 2024, 51(5): 298-302.
[4]	张丽丽, 谭茹, 房雪利, 杨宇, 桑铮, 李宝生. 乳腺导管原位癌影像学诊断、病理学升级及影像学技术进展[J]. 国际肿瘤学杂志, 2024, 51(3): 166-169.
[5]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[6]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[7]	崔腾璐, 孙鹏飞. 鼻咽低级别乳头状腺癌综合治疗1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(6): 382-384.
[8]	陈卓, 陶俊, 陈琳, 柯晶. 外周血miR-194联合粪便miR-143检测对结直肠癌临床筛查的价值[J]. 国际肿瘤学杂志, 2023, 50(5): 268-273.
[9]	顾安琴, 龙金华, 金风. 鼻咽癌免疫治疗的临床研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 299-303.
[10]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 同步放化疗期间应用聚乙二醇化重组人粒细胞刺激因子中国专家共识（2023版）[J]. 国际肿瘤学杂志, 2023, 50(4): 193-201.
[11]	黎立喜, 张娣, 罗扬, 马飞. PARP抑制剂在乳腺癌中的临床应用[J]. 国际肿瘤学杂志, 2023, 50(2): 91-96.
[12]	陈郁, 许华, 刘海, 陈士新. 基于CT影像学特征的恶性肺纯磨玻璃结节患者病理分型预测模型构建[J]. 国际肿瘤学杂志, 2023, 50(11): 655-660.
[13]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 新型冠状病毒感染疫情背景下肿瘤患者放射治疗管理相关问题中国专家共识（2023版）[J]. 国际肿瘤学杂志, 2023, 50(10): 577-584.
[14]	高一钊, 刘洋, 刘秋龙, 邢金良. 循环游离核酸在结直肠癌临床诊疗中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 555-559.
[15]	曾艳, 罗盼, 王子琪, 吴伟莉. 药物在头颈部肿瘤治疗中引起铁死亡的作用机制[J]. 国际肿瘤学杂志, 2022, 49(3): 173-176.